Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
GoodRx Holdings Inc (NASDAQ: GDRX) closed the day trading at $4.64 up 0.22% from the previous closing price of $4.63. In other words, the price has increased by $0.22 from its previous closing price. On the day, 0.8 million shares were traded. GDRX stock price reached its highest trading level at $4.71 during the session, while it also had its lowest trading level at $4.615.
Ratios:
For a better understanding of GDRX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.97 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.75. For the most recent quarter (mrq), Quick Ratio is recorded 5.32 and its Current Ratio is at 5.32. In the meantime, Its Debt-to-Equity ratio is 0.75 whereas as Long-Term Debt/Eq ratio is at 0.74.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on December 04, 2024, initiated with a Neutral rating and assigned the stock a target price of $5.
On August 09, 2024, Raymond James Upgraded its rating to Strong Buy which previously was Outperform but kept the price unchanged to $10.
RBC Capital Mkts Upgraded its Sector Perform to Outperform on May 23, 2024, whereas the target price for the stock was revised from $8 to $10.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 02 ’24 when Bradley Julie MB bought 95,255 shares for $4.95 per share.
Spectrum Equity VII, L.P. sold 10,677 shares of GDRX for $83,922 on Sep 03 ’24. The 10% Owner now owns 0 shares after completing the transaction at $7.86 per share. On Sep 03 ’24, another insider, Spectrum VII Investment Manage, who serves as the Affiliate of the company, bought 6,828 shares for $7.86 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GDRX now has a Market Capitalization of 1667328256 and an Enterprise Value of 1871153664. As of this moment, GoodRx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 108.92, and their Forward P/E ratio for the next fiscal year is 9.79. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 6.85. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.25 while its Price-to-Book (P/B) ratio in mrq is 2.45. Its current Enterprise Value per Revenue stands at 2.362 whereas that against EBITDA is 18.798.
Stock Price History:
The Beta on a monthly basis for GDRX is 1.25, which has changed by -0.34647888 over the last 52 weeks, in comparison to a change of 0.092895746 over the same period for the S&P500. Over the past 52 weeks, GDRX has reached a high of $9.26, while it has fallen to a 52-week low of $3.82. The 50-Day Moving Average of the stock is 1.35%, while the 200-Day Moving Average is calculated to be -19.63%.
Shares Statistics:
Over the past 3-months, GDRX traded about 1.42M shares per day on average, while over the past 10 days, GDRX traded about 692440 shares per day. A total of 105.95M shares are outstanding, with a floating share count of 88.88M. Insiders hold about 76.83% of the company’s shares, while institutions hold 16.07% stake in the company. Shares short for GDRX as of 1744675200 were 4771407 with a Short Ratio of 3.36, compared to 1741910400 on 5742411. Therefore, it implies a Short% of Shares Outstanding of 4771407 and a Short% of Float of 5.2299999999999995.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating for GoodRx Holdings Inc (GDRX) is a result of the insights provided by 12.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $0.1, with high estimates of $0.11 and low estimates of $0.09.
Analysts are recommending an EPS of between $0.46 and $0.35 for the fiscal current year, implying an average EPS of $0.4. EPS for the following year is $0.47, with 12.0 analysts recommending between $0.5 and $0.44.
Revenue Estimates
14 analysts predict $202.2M in revenue for the current quarter. It ranges from a high estimate of $204.99M to a low estimate of $200M. As of the current estimate, GoodRx Holdings Inc’s year-ago sales were $197.88MFor the next quarter, 14 analysts are estimating revenue of $206.3M. There is a high estimate of $211.5M for the next quarter, whereas the lowest estimate is $203.3M.
A total of 16 analysts have provided revenue estimates for GDRX’s current fiscal year. The highest revenue estimate was $836.28M, while the lowest revenue estimate was $812.5M, resulting in an average revenue estimate of $823.27M. In the same quarter a year ago, actual revenue was $792.32MBased on 16 analysts’ estimates, the company’s revenue will be $875.73M in the next fiscal year. The high estimate is $912.7M and the low estimate is $850.22M.
